Comparing Pfizer Stock and Merck and Co. Stock



Stock performance

As we discussed earlier, Pfizer (PFE) stock has risen ~5.8% to date in September, and its closing price was $43.93 on September 24, while Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.

The above chart compares Pfizer’s and Merck’s normalized stock prices for September. Pfizer’s market cap is ~$257.2 billion, while Merck & Co.’s market cap is ~$188.2 billion as of September 25.

Article continues below advertisement

Revenue and EPS performance 

Merck & Co. reported adjusted EPS of $1.06 on revenue of ~$10.5 billion in the second quarter, a 5.4% year-over-year rise in revenue compared to its adjusted EPS of $1.01 on revenue of ~$9.9 billion in the second quarter of 2017.

Technical indicators

Merck & Co. stock is currently trading ~1.8% higher than its 20-day simple moving average. The stock is also trading ~5.4% higher than its 50-day simple moving average and ~17.5% higher than its 200-day simple moving average as of September 24, which shows that its stock price could increase further in the near future.

Analysts’ recommendations

Analysts have given Merck & Co. a 12-month target price of $73.04 per share, a ~3.2% rise compared to its last price of $70.78 per share on September 24.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 5.1% in Merck & Co., 5.1% in Pfizer, 5.6% in Eli Lilly and Company (LLY), and 4.9% in Johnson & Johnson (JNJ).


More From Market Realist